ROSEMONT
SpecialtyROSEMONT is a specialty pharmaceutical company focused on Neurology, Cardiovascular. Key products include OZOBAX DS.
ROSEMONT at a Glance
- Strong track record with 88% execution quality across 12 trials
- Fast trial execution (33 months median completion)
ROSEMONT's Key Drugs
ROSEMONT's core commercial portfolio centers on OZOBAX DS, spanning Neurology and Cardiovascular — its most strategically important drugs approved in the last 15 years.
ROSEMONT's Recent FDA Approvals
New NDA/BLA approvals for ROSEMONT over the last two years — novel drugs only, excluding generics and label supplements.
ROSEMONT's Therapeutic Areas
ROSEMONT's approved drugs and pipeline span 2 therapeutic areas, led by Neurology and Cardiovascular, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
ROSEMONT's Top Competitors
ROSEMONT's closest competitors by therapeutic-area and drug-target overlap include GE HEALTHCARE, Novo Nordisk, and PAI HOLDINGS PHARM. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
ROSEMONT Pipeline Snapshot
Active clinical trials for ROSEMONT across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • OZOBAX DS leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Neurology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 0/0 completed
- • Speed: 33 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges